



## ACT\* for the treatment of malaria

### Composition:



**Artequin-300/375:** One blister contains 3 Lactab™ each containing 100 mg artesunate and 3 Lactab™ each containing 125 mg mefloquine base. One blisterpack contains 6 Lactab™ corresponding to one full treatment

**Artequin-600/750:** One blister contains 3 Lactab™ each containing 200 mg artesunate and 3 Lactab™ each containing 250 mg mefloquine base. One blisterpack contains 6 Lactab™ corresponding to one full treatment

**Artesunate** is fast acting (quick absorption, maximum plasma concentration between 0,5 to 1 hour; elimination half-life = 0,5 hours)

**Mefloquine** is long acting (slow absorption, maximum plasma concentration ca. 17 hours; elimination half-life = 21 days)

### Indication:

Oral treatment of uncomplicated *P. falciparum* malaria, including multi drug-resistant strains of *P. falciparum* as well as malaria caused by mixed *Plasmodium* pathogens.

### Dosage:

**Artequin-300/375:** Once daily 2 Lactab™ (one Lactab™ of artesunate and mefloquine each) for 3 consecutive days; **for patients with a bodyweight of 15 – 30 kg.**

**Artequin-600/750:** Once daily 2 Lactab™ (one Lactab™ of artesunate and mefloquine each) for 3 consecutive days; **for patients with a bodyweight of 30 – 55 kg.**

### ACT\*:

Artemisinin-based **C**ombination **T**herapies (ACT's) are the current "gold-standard" treatments for malaria, recommended by WHO and malaria experts

### Features:

- Currently used for therapy of semi-immune patients in Africa.
- Highly effective and well-tolerated. It provides up to 100 % cure rate with a simple treatment.
- Fast onset of action (fever and parasite clearance)
- Long-lasting therapeutic effect (up to 100 % cure rate, no recrudescence after 28 days)
- Patient friendly three-colour blister (better patient compliance).
- 1 single dose of 2 Lactab™ for 3 consecutive days – the patient is cured
- Top Swiss quality product, developed by Mepha Ltd, a pioneer in the field of malaria.

